Kate Gibson’s Post

Scientists at Dana-Farber Cancer Institute have developed a new CAR-Enhancer platform to enhance CAR-T cells in-vivo. A target antigen fused with a low-affinity enhancer molecule enables the precise targeting of the CAR-T cells to improve activity and persistence in the body. Importantly, it also promotes the development of memory CAR-T, helping to prevent cancer relapse. https://lnkd.in/ePEfiEAA

#transcript Sanjeev Redkar, Co-Founder, Executive Director, and President of Apollomics, focuses on difficult-to-treat cancers, such as lung cancer, brain cancer, and leukemias, not served by immune checkpoint inhibitors. Their approach targets the thematic pathway in cancer cells responsible for their growth and proliferation. In their drug development, AI and data analysis drive precision-targeted therapies based on tumor molecular profiling. Developing the drugs Vebreltinib and Uproleselan #RareDiseases #Cancer #LungCancer #Leukemias #BrainCancer #RareCancers #NextGenSequencing #MolecularProfiling #CancerMolecularProfiling #TumorMolecularProfiling Apollomics.com https://lnkd.in/gKSZaQAb

🎉 Congratulations to Alejandro B., a Latinos in Bio Member! 🎉 We are thrilled to celebrate Alejandro Balbin for his groundbreaking work, which has led to the FDA approval of Zenocutuzumab as a targeted therapy for cancers with NRG1 fusions, including pancreatic and non-small cell lung cancer (NSCLC). This approval comes 10 years after Alejandro’s discovery of these fusions during his PhD, marking a significant milestone in cancer research! Key Milestones: 🔸 Discovery of NRG1 fusions in NSCLC was published in 2014 in Nature Communications Read the paper here: https://lnkd.in/eKSnHX8K 🔸 FDA approval of Zenocutuzumab for cancers with NRG1 fusions, a major advancement for the treatment of pancreatic and lung cancers. Congratulations to the entire team behind this breakthrough, and to all those who will benefit from this therapy! #CancerResearch #PrecisionMedicine #FDAApproval #NSCLC #LatinosInBio #Innovation #MedicalBreakthrough

🧬 Breakthrough in Cancer Detection! New technology has emerged that detects cancer mutant genes with unprecedented sensitivity, a game-changer in early cancer diagnosis. Early detection is crucial in fighting cancer, but breakthroughs like this wouldn't be possible without clinical trials. Clinical trials are the backbone of medical advancements, providing the evidence needed to ensure new technologies are safe, effective, and ready to make a real-world impact. Patients who participate in these trials play a vital role in driving innovation and improving healthcare for everyone. Read more about this exciting development: https://buff.ly/3zbMbZU #CancerResearch #ClinicalTrials #HealthcareInnovation #EarlyDetection #MedicalBreakthrough

#Cancer, a pervasive and multifaceted disease, arises from the uncontrolled growth and spread of abnormal cells within the body. This relentless condition impacts millions #worldwide, disrupting lives and challenging #medical communities. At #G2M, we are at the forefront of innovative #oncology detection methods, harnessing the power of #RTPCR technology. Our in-vitro #diagnostic tests are designed for precise detection and provide valuable information for the prognosis and management of cancer patients, and it may serve as a useful adjunct to clinical decision-making in the future. Click here to read more...

While the world of cancer screening and early detection is not new, our health care industry is not winning the war on cancer - but it doesn't have to be this way. miRoncol CEO Victoria Xu recently spoke with GenomeWeb about how our goal with miRoncol is to democratize access to early detection for cancer screening while offering an affordable and accurate alternative to the existing tests on the market today. Want to learn more? Read here: https://lnkd.in/eCi7VBcd

Exciting news from the forefront of medical innovation: Delfi Diagnostics has revealed promising results from a proof-of-concept study at the American Association for Cancer Research's annual meeting, in the early detection of ovarian cancer. Leveraging the technology behind their FirstLook liquid biopsy for lung cancer, they've shown that whole-genome sequencing combined with machine learning can effectively identify cancerous patterns in DNA. This breakthrough could be a game-changer in cancer screening, offering hope for earlier detection and treatment. #MedicalInnovation #CancerResearch #EarlyDetection

📖 WEEKEND READ | How Automating Flow Cytometry is Revolutionising Cancer Diagnosis and Treatment Our Sandra Hernandez, Senior Commercial Product Manager of Clinical Flow Cytometry, shares with pharmaphorum how automation is enabling improvements across the entire flow cytometry workflow, and shares one lab's powerful improvements in bringing precise, actionable answers to more cancer patients than ever before. Full story: https://becls.co/3ZC42no #DanaherNews #Diagnosis #FlowCytometry

【Cited FineTest ELISA Kit】IL-10 ELISA Kit | Molecular Cancer | IF: 37.3 Abstract:  FineTest IL-10 ELISA Kit is cited by an article entitled "Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression" Published in Molecular Cancer. (Read Full Text: https://bit.ly/4ckeWlZ) Keywords: #GastricCancer, #TumorMicroenvironment, #CancerResearch, #CancerTreatment

The Biden administration offers a three-arm pathway to modernize genomic testing and clinical oncology. It's created under ARPA-H and called "ADAPT." With an emphasis on tumor tracking and evolution, let's add a call to retire (and ASAP) the crazy "one tumor, one test rule" for NGS testing under CMS NCD 90.2. The NCD's text is increasingly a setback for Medicare patients with cancer. See details and a longer discussion of ARPA-ADAPT, at blog. #cancer #cms #nih #nci #arpa #genomics #ncd https://lnkd.in/g6WgnYTA